On September 7, 2018, Biotechnology Innovation and Development Summit in Guangdong-Hong Kong-Macao Greater Bay Area and Top 50 Innovative Enterprises Awarding Ceremony were jointly held by ZDVC Research and KPMG China in Pazhou Exhibition Center, Guangzhou.

Biomedical experts and scholars, investors and medical researchers in Guangdong-Hong Kong-Macao Greater Bay Area attended and witnessed the summit and award ceremony, including Wei Jizhang, Former Deputy Inspector of Guangdong Provincial Development and Reform Commission, Liao Zibin, Chairman of KPMG China, Shu Yuan, Chairman of ZDVC Group, Xie Jiasheng, CEO of Guangdong Medical Valley, Xu Xiaoliang, Deputy General Manager of PICO of CFDA Southern Medicine Economic Research Institute, and Hu Wenhao, Dean of Pharmaceutical Sciences School, Sun Yat-Sen University. As one of the top 50 winners, Longtime Pharmaceutical attended the event.

The concept of Guangdong-Hong Kong-Macao Greater Bay Area was first proposed at the two sessions in 2017. The Urban Agglomeration Development Strategy in Guangdong-Hong Kong-Macao Greater Bay Area, which has been upgraded to a national strategy, puts forward higher requirements for the development of biomedical industry. It requires not only to improve resource allocation capability and industrial chain leading function, but also to further enhance the external economic radiation capability. The selection of the top 50 biotechnology innovation enterprises in Guangdong-Hong Kong-Macao Greater Bay Area is just for the purpose of adapting to the industrial integration development under the national strategy, clearly sorting out and recording the development history of biotechnology innovation in Guangdong-Hong Kong-Macao Greater Bay Area, and promoting the in-depth development of the entire industry.

This selection activity has received support and attention from many well-known enterprises and institutions. The judge panel consisted of more than 20 professionals from government agencies, third-party research institutes, professional investment and medical institutions. The judges conducted in-depth research on enterprises through documents and interviews, and comprehensively evaluated the technological innovation and future development prospects of the participating enterprises from the three dimensions, i.e. leading technology application and breakthrough, market application, valuation and capital market recognition. After more than three months of preparation and implementation, the list of the top 50 biotechnology innovation enterprises in Guangdong-Hong Kong-Macao Greater Bay Area has been released.

Photo of some enterprises winning the award